• Minicabecera4

Histocell commits to manufacturing in the Basque Country with the opening of a production centre in Larrabetzu

Histocell Factory Opening

Histocell has inaugurated its new production centre in Larrabetzu, dedicated to the manufacture of medical devices for regenerative medicine. The plant, which required an investment of 1.6 million euros and will initially generate 10 jobs and 30 additional jobs in the coming years, demonstrates the company's commitment to maintaining both its research and manufacturing activities in the Basque Country.

This aspect has been highlighted at the inauguration ceremony by the General Deputy of Bizkaia, Unai Rementeria, the Basque Government Economic Development and Competitiveness Minister, Arantxa Tapia, and the mayor of Larrabetzu, Iñigo Gaztelu, who visited the facilities with the General Manager and the Deputy General Manager of Histocell, Julio Font and Marta Acilu, respectively. All have agreed to underline ‘the innovative character of a biotechnological company that completes the entire cycle, from applied research in its laboratories to the commercialization of its products including their local production, which is the main reason for building this manufacturing plant. In addition, everything is done from the Basque Country with technology and patents also developed here.’

The new manufacturing plant joins the GMP clean room accredited by the Spanish Agency of Medicines and Medical Devices, which is located on the premises of the firm at the Science and Technology Park of Bizkaia in Derio, where Histocell will continue manufacturing its stem cell-based therapy drugs. These drugs are currently in clinical phase trials in several Spanish hospitals. Results from the first patients treated with these cell-based drugs are very promising.

In Larrabetzu, manufacturing will be focused on the line of products for the treatment of hard to heal wounds, Reoxcare, and on the dermocosmetics products, Wharton Gel Complex and Histoessence. Reoxcare is already being marketed in Europe, America, Asia and the Middle East through different distribution agreements, and Osakidetza, the Basque Health Service, is one of Reoxcare’s customers. Rexocare is an innovative wound dressing, unique in the international market, which is produced with materials from natural origin. It has clearly demonstrated its differential value in the healing of complex wounds where other conventional treatments have failed. In the new plant in Larrabetzu, Histocell foresees an annual production of 100,000 units of the dressings, 400 kilograms of the cosmetic ingredient Wharton Gel Complex, and up to 200,000 vials of Histoessence. In total, the company estimates that the products manufactured in the new facilities will reach sales of 6 million euros in 2021.

Capital increase with a Japanese investment fund

The inauguration is not the only business milestone reached by the biopharmaceutical company this year. The company has also significantly increased its capital as the result of the entry of the Japanese investment fund Cell Innovation Partners that specializes in regenerative medicine and cell therapy and whose main partners are the Japanese company Reprocell and bank Shinsei. This is the first investment of this fund in a biopharmaceutical company in Spain. In this financing round, the main current partners of Histocell have also participated.

Histocell has undertaken the necessary investments to start its new manufacturing centre in Larrabetzu with the support of the 3i programmes of integral support for innovation, investment and internationalisation from the Provincial Council of Bizkaia and the Gauzatu program from the Basque Government dedicated to promoting the creation and development of innovative and technology-based SMEs.